/ News / Improving the health of Canadians with diabetes-- Dr. Dan Drucker
recognized for exceptional contributions to diabetes research and patient care in Canada
(January 23, 2012-Toronto, ON) Dr. Daniel Drucker, Senior Investigator at the Samuel Lunenfeld Research Institute of Mount Sinai Hospital, Professor of Medicine and Director of the Banting and Best Diabetes Centre at the University of Toronto, has received a 2011 CIHR/CMAJ Top Achievements in Health Research Award, in recognition of his internationally renowned achievements in diabetes patient care and research.
was one of six recipients of the award, included among exceptional researchers in Canada whose achievements changed the course of health care delivery in their field of work.
For the third year, a peer-review panel of Canadian and international experts selected exceptional individuals including Dr. Drucker
, based on the considerable health impact of their work to benefit Canadians and others worldwide.
Among the six outstanding achievements selected, Dr. Drucker
was one of only two who received special mentions for their highest-ranking successes.
"I am very pleased that the hard work and accomplishments of our research team over two decades have led to a greater understanding of the biology of gut hormones, and in turn, the development of new drugs for the treatment of diabetes," said Dr. Drucker
New therapies are greatly improving blood sugar control for people with diabetes-an illness that impacts thousands of Canadians.
The two most recently approved drug classes for the treatment of type 2 diabetes, DPP-4 inhibitors and GLP-1R agonists (both widely used in Canada and helping to improve glucose control and quality of life), are based substantially on Dr. Drucker's research
is now investigating the cardiovascular effects of these drugs, in parallel with seven major clinical cardiovascular outcome studies that are underway to rigorously assess the safety of these new drugs in patients with diabetes and heart disease.
also contributed to the testing of a new once-weekly treatment for type 2 diabetes that may complement the more common twice-daily injection of exenatide, an advance that has significantly improved the quality of life for people with diabetes.
A clinician-scientist at Mount Sinai since 2007, Dr. Drucker's leadership and achievements in diabetes research at the hospital have received both national and international recognition.
This reflects the remarkable impact Dr. Drucker
has had on patients suffering from diabetes."
Later this year, Dr. Drucker
will become the first and only Canadian to receive the Claude Bernard Lecture/Award of the European Association for the Study of Diabetes
(EASD), which is thehighest scientific achievement award of the EASD
holds the Canada Research Chair in Regulatory Peptides; received the Prix Galien Canada Research Award in 2008 for his
substantial contribution to the diagnosis, prevention or treatment of diseases; and the 2009 Clinical Investigator Award from The Endocrine Society
The incidence of type 2 diabetes has reached epidemic proportions worldwide and is a leading cause of heart disease, stroke, blindness, kidney failure and limb amputation.
Several studies have shown that lifestyle changes and appropriate pharmacologic therapy can significantly reduce the development of type 2 diabetes in people at risk of the disease.
significant research discoveries mean improved health for millions of patients with type 2 diabetes worldwide.
key findings led to the development of several new classes of therapies for these patients.
The new therapies reduced the need for self-monitoring of blood glucose levels and lowered the risk of hypoglycemia and weight gain.
Currently, Dr. Drucker's
lab at the Lunenfeld
focuses on understanding the biology of glucagon-like peptides.